Table 2. Prevalence and Percentage of Antimicrobial Resistance among the Gram-Negative Isolates a.
| No. | AMC | SAM | FEP | CFP | CTX | CXM | CAZ | CRO | CL | CE | CEC | CFM | IPM | MEM | ATM | AK | CN | TOB | DO | NA | CIP | LEV | NOR | OFX | MOX | SXT | F | PIP | SCF | TZP | FOS | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E. coli | 244 | 84 | 84 | 71 | 72 | 72 | 80 | 71 | 71 | 95 | 95 | 79 | 71 | 3 | 3 | 72 | 91 | 47 | 59 | 81 | 91 | 82 | 82 | 81 | 82 | 82 | 78 | 20 | 92 | 3 | 4 | 10 |
| Klebsiella spp. | 5 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 100 | 100 | 40 | 40 | 20 | 20 | 40 | 20 | 40 | 40 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 40 | 0 | 20 | 20 | 20 | 40 |
| Proteus spp. | 3 | 67 | 67 | 67 | 67 | 67 | 67 | 67 | 67 | 100 | 100 | 67 | 67 | 0 | 0 | 67 | 33 | 67 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 67 |
| Pseudomonas spp. | 23 | NT | NT | 39 | NT | NT | NT | 48 | NT | NT | NT | NT | NT | 22 | 22 | 30 | 22 | 43 | NT | NT | NT | 57 | 57 | 57 | 57 | 57 | NT | NT | NT | NT | 13 | NT |
a Abbreviations: AMC, Amoxicillin/clavulanic acid; AK, Amikacin; ATM, Aztreonam; CAZ, Ceftazidime; CE, Cephradine; CEC, Cefaclor; CFP, Cefoperazone; CFM, Cefixime; CL, Cephalexin; CN, Gentamicin; CIP, Ciprofloxacin; CRO, Ceftriaxone; CTX, Cefotaxime; CXM, Cefuroxime; DO, Doxycycline; FEP, Cefepime; FOS, Fosfomycin; IPM, Imipenem; LEV, Levofloxacin; MEM, Meropenem; MOX, Moxifloxacin; NA, Nalidixic acid; NOR, Norfloxacin; NT, Not Tested; OFX, Ofloxacin; PIP, Pipemidic acid; SAM, Ampicillin/sulbactam; SCF, Cefoperazone/sulbactam; SXT, Trimethoprim/sulfamethoxazole F Nitrofurantoin; TOB, Tobramycin; TZP, Piperacillin/tazobactam.